

Form PTO-1449 U.S. Department of Commerce
(REV. 2-82) Patent and Trademark Office

Atty. Docket No.
34894-PCT-USA
(072745.0128)

Serial No.
10/019,613

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**
(Use several sheets if necessary)

Applicant
Cortendo AB

Filing Date
December 28, 2001

Group 1614
~~Not Yet Assigned~~

U.S. PATENT DOCUMENTS

*Exam. Init.	Document No.	Date	Name	Class	Subclass	Filing Date if Appropriate
<u>12.</u>	4 6 0 3 1 4 1	7/29/86	Giles			

FOREIGN PATENT DOCUMENT

	Document No.	Date	Country	Class	SubClass	Translator Yes No
<u>1.</u>	0 0 2 4 4 0 2	4 May 2000	WIPO			
<u>2.</u>	0 0 1 8 4 2 4	6 April 2000	WIPO			

OTHER DOCUMENTS (including Author, Title Date, Pertinent Pages, Etc.)

<u>3.</u>	Faggiano P, D'Aloia A, Gualeni A, Giordano A. Hemodynamic profile of submaximal constant workload exercise in patients with heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1998 Fe 15;81(4):437-442.
<u>4.</u>	Ganiats TG, Browner DK, Dittrich HC. Comparison of Quality of Well-Being scale and NYHA functional status classification in patients with atrial fibrillation. New York Heart Association. Am Heart J 1998 May;135(5 Pt 1):819-824.
<u>5.</u>	Spitz IM, Bardin CW. Mifepristone (RU 486)--a modulator of progestin and glucocorticoid action. N Engl J Med 1993 Aug 5;329(6):404-412.
<u>6.</u>	Scheuer DA, Mifflin SW. Chronic cortisone treatment increases myocardial infarct size in rats with ischemia reperfusion injury. Am J Physiol 1997 Jun;272(6 Pt 2):R2017-2024.
<u>7.</u>	Rotstein DM, Kertesz DJ, Walker KA, Swinney DC. Stereoisomers of ketoconazole: preparation and biologic activity. J Med Chem 1992 Jul 24;35(15):2818-2825.
<u>8.</u>	Dvortsin GF. Use of a synthetic opioid for the reversal of stress-induced damage of the myocardium and gastric mucosa in severe thermal trauma [In Russian]. Kardiologiia 1989 Sep;29(9):81-83.

NY02:362232.1

Examiner

Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce
(REV. 2-82) Patent and Trademark Office

Atty. Docket No.
34894-PCT-USA
(072745.0128)

Serial No.
10/019,613

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

(Use several sheets if necessary)

Applicant
Cortendo AB

Filing Date
December 28, 2001

Group 1614
~~Not Yet Assigned~~

9.			Aggernaes H, Kirkegaard C, Magelund G. The effect of sodium valproate on serum cortisol levels in healthy subject and depressed patients. Acta Psychiatr Scand 1988 Feb;77(2):170-174.
10.			Slowinska-Srzednicka J, Zgliczynski S, Soszynski P, Pucilowska J, Wierzbicki M, Jeske W. Effect of clonidine o beta-endorphin, ACTH and cortisol secretion in essential hypertension and obesity. Eur J Clin Pharmacol 1988;35(2):115-121.
11.			Legros JJ, Chiodera P, Geenen V, von Frenckell R. Confirmation of the inhibitory influence of exogenous oxytocin o cortisol and ACTH in man: evidence of reproducibility. Acta Endocrinol (Copenh) 1987 Mar;114(3):345-349.
13.			Loose DS, Stover EP, Feldman D. Ketoconazole binds to glucocorticoid receptors and exhibits glucocorticoid antagonist activity in cultured cells. J Clin Invest 1983 Jul;72(1):404-408.
14.			Stubbs WA, Delitala G, Jones A, Jeffcoate WJ, Edwards CR, Ratter SJ, Besser GM, Bloom SR, Alberti KG. Hormonal and metabolic responses to an enkephalin analogue in normal man. Lancet 1978 Dec 9;2(8102):1225-1227

NY02:362232.1

Examiner

Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.